Vedanta Biosciences has received a research grant from CARB-X to support the development of an anti-infective to treat hospital-acquired infections by multi-drug resistant organisms (MDRO).

The company will use the $5.8m grant to develop its preclinical human microbiome-derived candidate, VE707, for oral administration.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

VE707 is intended to restore a healthy microbiota and also prevent infection and colonisation recurrence of various MDRO in high-risk patients.

Vedanta Biosciences is developing the drug candidate to remove carbapenem-resistant Enterobacteriaceae (CRE), extended-spectrum beta lactamase producers (ESBL) and vancomycin-resistant Enterococci (VRE) present in the intestine.

Infections caused by CRE, ESBL and VRE are known to occur in more than 500,000 intensive care unit, dialysis, solid organ transplant and haematopoietic stem cell transplant patients in the US and Europe annually.

These infections are estimated to add nearly $2bn to healthcare costs for patient isolation practices.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Vedanta Biosciences CEO Bernat Olle said: “If we could get rid of intestinal carriage of these MDROs in high-risk patients, we could not only prevent infections but also curb the transmission of these organisms and enable physicians to avoid using antibiotics that select for ever-more resistant bacterial strains.”

As well as from the $5.8m grant, the company may receive $3.5m upon achieving certain milestones.

CARB-X executive director Kevin Outterson said: “The addition of Vedanta’s VE707 programme to the CARB-X portfolio expands the rich diversity of our pipeline and reflects a novel approach against drug-resistant infections.

“Innovations such as VE707, if successful and approved for use in patients, could offer physicians broader treatment options that would strengthen a patient’s ability to fight serious infections and limit the spread of drug-resistant bacteria.”

In 2017, CARB-X provided $5.4m to the company for clinical testing of VE303 to treat recurrent Clostridioides difficile infection (rCDI).